

101 743449

COPI

PH7483 NP

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sammy G. Duncan, Jr.

Type or print name

Signature

11/2/06

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Certificate of Corrections Branch  
Commissioner for Patents  
PO BOX 1450  
Alexandria, VA 22313-1450**

IN RE APPLICATION OF  
**TAEKYU LEE, ET AL**  
PATENT NO: 7109339  
FILED: 12/19/2003

**FOR: SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS  
SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS**

**Certificate  
NOV 08 2006  
of Correction**

**REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT****FOR PTO MISTAKE (37 C.F.R. §1.322(a))**

Sir:


Attached, in duplicate, is Form PTO-1050, with at least one copy being suitable for printing.

In that this error was incurred by the Office, no fee is believed to be due. If any fee not accounted for is due in connection herewith, please charge such fee to Deposit Account No. 19-3880 of the undersigned.

Please send the Certificate to the address associated with customer account number 23914.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

  
\_\_\_\_\_  
Sammy G. Duncan, Jr., Ph.D.  
Attorney for Applicant  
Reg. No. 46,675  
Phone: 609-252-6270  
Date: 11/2/06

**(NOV - 9 2006)**

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO : 7,109,339  
 DATED: : September 19, 2006  
 INVENTOR(S) : Taekyu Lee et al.

Page 1 of 2

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims: Column 160, Line 35 insert the following:

C<sub>3-10</sub> carbocyclic residue substituted with 0-3 R<sup>41</sup>, and

5-6 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of

N, O, and S substituted with 0-3 R<sup>41</sup>;

R<sup>2a</sup> is H, C<sub>1-4</sub> alkyl, (aryl)C<sub>1-4</sub> alkyl-, or

(C<sub>3-6</sub> cycloalkyl)C<sub>1-4</sub> alkyl-;

R<sup>4a</sup> is H or C<sub>1-4</sub> alkyl;

R<sup>5</sup> is H, C<sub>1-4</sub> alkyl substituted with 0-2 R<sup>20</sup>,

-C(=O)(C<sub>1-4</sub> alkyl), -C(=O)O(C<sub>1-4</sub> alkyl), or C<sub>1-4</sub> haloalkyl;

R<sup>6</sup> is selected from

-OCF<sub>3</sub>, -SCH<sub>3</sub>, -CF<sub>2</sub>CF<sub>3</sub>, -O-R<sup>11</sup>,

-OCF<sub>2</sub>CF<sub>3</sub>, -OCF<sub>2</sub>H, -OCF<sub>2</sub>CH<sub>3</sub>,

-S(=O)-R<sup>11</sup>, -S(=O)<sub>2</sub>-R<sup>11</sup>, -S(=O)-NR<sup>10</sup>-R<sup>11</sup>,

-S(=O)<sub>2</sub>-NR<sup>10</sup>-R<sup>11</sup>, -CH<sub>2</sub>O-R<sup>11</sup>, -CH<sub>2</sub>S-R<sup>11</sup>,

CH<sub>2</sub>S(=O)-R<sup>11</sup>, CH<sub>2</sub>S(=O)<sub>2</sub>-R<sup>11</sup>, -CH<sub>2</sub>NR<sup>10</sup>-R<sup>11</sup>, -C(=O)NR<sup>10</sup>-R<sup>11</sup>

C<sub>1-4</sub> haloalkyl, (C<sub>1-4</sub> haloalkyl)oxy;

C<sub>2-4</sub> alkenyl substituted with 0-2 R<sup>20</sup>,

C<sub>2-4</sub> alkynyl substituted with 0-1 R<sup>20</sup>, and

C<sub>3-6</sub> carbocyclic residue substituted with 0-3 R<sup>21</sup>,

R<sup>7</sup> and R<sup>9</sup> are independently selected from

-OCF<sub>3</sub>, -CF<sub>2</sub>CF<sub>3</sub>, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> haloalkyl, and

(C<sub>1-4</sub> haloalkyl)oxy;

NOV - 9 2006

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO : 7,109,339  
DATED: : September 19, 2006  
INVENTOR(S) : Taekyu Lee et al.

Page 2 of 2

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims: Claim 3, Column 166, Line 26 replace:

$R^4a$  with  $R^{4a}$

MAILING ADDRESS OF SENDER:  
Sammy G. Duncan, Jr., Ph.D.  
Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-6270

PATENT NO. 7,109,339

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO : 7,109,339  
 DATED: : September 19, 2006  
 INVENTOR(S) : Taekyu Lee et al.

Page 1 of 2

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims: Column 160, Line 35 insert the following:

C<sub>3-10</sub> carbocyclic residue substituted with 0-3 R<sup>41</sup>, and

5-6 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of  
 N, O, and S substituted with 0-3 R<sup>41</sup>;

R<sup>2a</sup> is H, C<sub>1-4</sub> alkyl, (aryl)C<sub>1-4</sub> alkyl-, or  
 (C<sub>3-6</sub> cycloalkyl)C<sub>1-4</sub> alkyl-;

R<sup>4a</sup> is H or C<sub>1-4</sub> alkyl;

R<sup>5</sup> is H, C<sub>1-4</sub> alkyl substituted with 0-2 R<sup>20</sup>,  
 -C(=O)(C<sub>1-4</sub> alkyl), -C(=O)O(C<sub>1-4</sub> alkyl), or C<sub>1-4</sub> haloalkyl;

R<sup>6</sup> is selected from

-OCF<sub>3</sub>, -SCH<sub>3</sub>, -CF<sub>2</sub>CF<sub>3</sub>, -O-R<sup>11</sup>,  
 -OCF<sub>2</sub>CF<sub>3</sub>, -OCF<sub>2</sub>H, -OCF<sub>2</sub>CH<sub>3</sub>,  
 -S(=O)-R<sup>11</sup>, -S(=O)<sub>2</sub>-R<sup>11</sup>, -S(=O)-NR<sup>10</sup>-R<sup>11</sup>,  
 -S(=O)<sub>2</sub>-NR<sup>10</sup>-R<sup>11</sup>, -CH<sub>2</sub>O-R<sup>11</sup>, -CH<sub>2</sub>S-R<sup>11</sup>,  
 CH<sub>2</sub>S(=O)-R<sup>11</sup>, CH<sub>2</sub>S(=O)<sub>2</sub>-R<sup>11</sup>, -CH<sub>2</sub>NR<sup>10</sup>-R<sup>11</sup>, -C(=O)NR<sup>10</sup>-R<sup>11</sup>  
 C<sub>1-4</sub> haloalkyl, (C<sub>1-4</sub> haloalkyl)oxy;  
 C<sub>2-4</sub> alkenyl substituted with 0-2 R<sup>20</sup>,  
 C<sub>2-4</sub> alkynyl substituted with 0-1 R<sup>20</sup>, and  
 C<sub>3-6</sub> carbocyclic residue substituted with 0-3 R<sup>21</sup>,

R<sup>7</sup> and R<sup>9</sup> are independently selected from

-OCF<sub>3</sub>, -CF<sub>2</sub>CF<sub>3</sub>, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> haloalkyl, and  
 (C<sub>1-4</sub> haloalkyl)oxy;

NOV - 9 2006

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO : 7,109,339  
DATED: : September 19, 2006  
INVENTOR(S) : Taekyu Lee et al.

Page 2 of 2

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims: Claim 3, Column 166, Line 26 replace:

$R^{4a}$  with  $R^{4a}$

MAILING ADDRESS OF SENDER:  
Sammy G. Duncan, Jr., Ph.D.  
Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-6270

PATENT NO. 7,109,339